Latest Headlines

  1. Seek Labs Unveils Investigational, Equipment-Free Molecular Prototype For MTB On Rapid-Deploy SeekIt Platform 8/13/2025

    Seek Labs, a biotech company boldly seeking a healthier world through AI-powered discovery, programmable therapeutics, and point-of-care diagnostics, today announced a significant advancement in the global fight against tuberculosis (TB) with an investigational prototype for Mycobacterium tuberculosis (MTB) detection on its SeekIt platform.

  2. Techcyte And Modella AI Announce A Research Collaboration With Modella AI's State-Of-The-Art Agentic And Generative AI-Powered Diagnostic Pathology Platform 8/12/2025

    Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its platform, Techcyte Fusion (research use only (RUO) in the US, CE-IVDD-marked in Europe), now includes Modella AI, a biomedical artificial intelligence company at the forefront of computational pathology, as a partner in the Techcyte Fusion Partner Program.

  3. Copan Launches UriVerse™: Fully Automated Solution For Urine Specimen Aliquoting 8/12/2025

    Copan, a leader in microbiology laboratory and automation innovations, proudly announced the official launch of UriVerse™ during the Association for Diagnostics & Laboratory Medicine (ADLM) Clinical Lab Expo in Chicago, IL.

  4. Thermo Fisher Receives FDA Approval For NGS-Based Companion Diagnostic For New Non-Small Cell Lung Cancer Treatment 8/11/2025

    Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be candidates for HERNEXEOS (zongertinib tablets), a tyrosine kinase inhibitor (TKI), developed by Boehringer Ingelheim.

  5. HistoIndex Marks Another Step Forward With FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis In Fibrosis Assessment 8/11/2025

    HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch of FibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States.

  6. Haier Biomedical Supports Macao's Key TCM Lab 8/8/2025

    The State Key Laboratory of Quality Research in Chinese Medicine (University of Macau)—one of the first state key laboratories established in Macao—is turning to Haier Biomedical's advanced equipment to help break through research bottlenecks in its traditional Chinese medicine (TCM) innovation.

  7. Blood-Based Test Provides New Diagnostic Approach For Multiple Myeloma 8/8/2025

    Researchers at Dana-Farber Cancer Institute, Massachusetts General Hospital (MGH), and the Broad Institute have developed a blood test that could transform the diagnosis and monitoring of multiple myeloma (MM) and its precursor conditions.

  8. Anbio Biotechnology Responds To Global Outbreaks With Chikungunya Rapid Test And New 15-Minute Ultra-Fast PCR System 8/8/2025

    In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of care.

  9. Bringing Advanced Vascular Diagnostics To The Western US With The SmartVascular Dx™ Test 8/8/2025

    MorningStar Laboratories, LLC., (“MSL” or “the Company”), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now available in the Western United States.

  10. C2N Announces Major Global Expansion, Adds Six New International Partners 8/7/2025

    C2N Diagnostics, LLC (“C2N”), a specialty diagnostics company with a vision to bring Clarity Through Innovation, is reaching additional global healthcare providers eager to use its PrecivityAD2 blood test to help diagnose Alzheimer’s disease.